We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-4.77%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.53B
AUM Growth
+$158M
Cap. Flow
+$341M
Cap. Flow %
22.28%
Top 10 Hldgs %
52.34%
Holding
81
New
20
Increased
20
Reduced
13
Closed
17

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$69.5M
2
MDT icon
Medtronic
MDT
+$50.4M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$33.1M
4
LLY icon
Eli Lilly
LLY
+$32M
5
PTCT icon
PTC Therapeutics
PTCT
+$28.9M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$63.9M
2
AZN icon
AstraZeneca
AZN
+$42.7M
3
GILD icon
Gilead Sciences
GILD
+$36.7M
4
AXSM icon
Axsome Therapeutics
AXSM
+$36M
5
BSX icon
Boston Scientific
BSX
+$31M

Sector Composition

Rank Sector Weight
1 Healthcare 86.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMNM icon
51
Immunome
IMNM
$2.63B
$5.31M 0.35%
788,666
+41,842
+6% +$401K
KURA icon
52
Kura Oncology
KURA
$826M
$5.23M 0.34%
+791,667
New +$6.17M
INZY
53
DELISTED
Inozyme Pharma
INZY
$3.9M 0.25%
4,280,308
– –
SRRK icon
54
Scholar Rock
SRRK
$5.92B
$3.73M 0.24%
+116,117
New +$4.47M
ERAS icon
55
Erasca
ERAS
$6.3B
$2.57M 0.17%
1,877,085
+81,205
+5% +$139K
NXTC icon
56
NextCure
NXTC
$22.1M
$1.28M 0.08%
222,655
– –
ESTA icon
57
Establishment Labs
ESTA
$2.7B
$1.17M 0.08%
28,675
-66,630
-70% -$2.48M
BOLT icon
58
Bolt Biotherapeutics
BOLT
$7.72M
$1.1M 0.07%
137,722
– –
MTSR
59
DELISTED
Metsera Inc
MTSR
$1M 0.07%
+36,800
New +$1.04M
ELVN icon
60
Enliven Therapeutics
ELVN
$3.84B
$660K 0.04%
33,547
-478
-1% -$10.3K
GPCR icon
61
Structure Therapeutics
GPCR
$3.4B
$605K 0.04%
34,952
+14,060
+67% +$344K
VIR icon
62
Vir Biotechnology
VIR
$1.49B
$538K 0.04%
83,010
-31,121
-27% -$277K
IMA
63
ImageneBio Inc
IMA
$65.5M
$490K 0.03%
31,885
– –
IRON icon
64
Disc Medicine
IRON
$2.85B
$372K 0.02%
7,485
-15,267
-67% -$849K
ABBV icon
65
AbbVie
ABBV
$465B
– –
-359,393
Closed -$63.9M
ACHV icon
66
Achieve Life Sciences
ACHV
$634M
– –
-1,306,482
Closed -$4.6M
ALKS icon
67
Alkermes
ALKS
$8.42B
– –
-894,266
Closed -$25.7M
AVTR icon
68
Avantor
AVTR
$8.48B
– –
-200,000
Closed -$4.21M
AXSM icon
69
CALL
Axsome Therapeutics
AXSM
$12.1B
– –
-100,000
Closed -$8.46M
AZN icon
70
AstraZeneca
AZN
$267B
– –
-325,672
Closed -$42.7M
BDX icon
71
Becton Dickinson
BDX
$45.8B
– –
-4,951
Closed -$1.12M
BSX icon
72
Boston Scientific
BSX
$68.5B
– –
-346,571
Closed -$31M
EW icon
73
Edwards Lifesciences
EW
$48.2B
– –
-40,000
Closed -$2.96M
EXAS
74
DELISTED
Exact Sciences
EXAS
– –
-52,042
Closed -$2.92M
GMED icon
75
Globus Medical
GMED
$10.9B
– –
-244,700
Closed -$20.2M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2025 Portfolio in Review

As of Q1 2025, Sofinnova Investments held 81 positions worth $1.53B, up 12% from $1.37B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Sofinnova Investments deployed $341M of net new capital in Q1 2025, opening 20 new positions and adding to 20 existing holdings. Its largest new stake was Medtronic: 562,992 shares worth $50.6M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Gilead Sciences, an estimated $36.7M trimmed.

  • Sofinnova Investments's largest Q1 2025 buy was Medtronic: 562,992 shares worth $50.6M.
  • Sofinnova Investments added most to Stryker in Q1 2025, an estimated $69.5M increase.
  • Sofinnova Investments's biggest Q1 2025 reduction was Gilead Sciences, cutting an estimated $36.7M.
  • Sofinnova Investments fully exited AbbVie in Q1 2025, selling an estimated $63.9M.
  • Sofinnova Investments's ten largest holdings make up 52% of its $1.53B portfolio in Q1 2025.
  • Sofinnova Investments opened 20 new positions and closed 17 in Q1 2025.
  • Sofinnova Investments's portfolio value rose 12% quarter-over-quarter to $1.53B.

Based on Sofinnova Investments's 13F filing for Q1 2025, filed 15 May 2025.